Oryzon Genomics today announced that the United States Patent and Trademark Office has granted U.S. patent US12,564,559 B2, relating to therapeutic combinations of iadademstat, Oryzon’s potent and s...
Read more
Researchers from Clínic-IDIBAPS, as part of the Clínic Barcelona Comprehensive Cancer Centre — a centre driven by Clínic, IDIBAPS and the University of Barcelona — have developed a new version ...
Read more
Han descifrado el mecanismo molecular que explica la variabilidad clínica en pacientes con trastornos relacionados con el gen MYH9. El estudio revela por qué distintas mutaciones en un mismo gen pue...
Read more
Demuestran cómo una deleción (un tipo de mutación) en el cromosoma 9, al inactivar parcialmente los genes PAX5 y CD72, desencadena el desarrollo de leucemia linfoblástica aguda de células B, uno ...
Read more
Han demostrado por primera vez un beneficio clínico real de la vacunación frente a la gripe en pacientes altamente inmunosuprimidos, concretamente en receptores de trasplante alogénico de progenito...
Read more
A study reveals that this chromosomal instability caused by hyperdiploidy reduces the proliferation of the affected cells, delays their differentiation and allows some to persist as rare, long-lived c...
Read more
Con los años, las mujeres presentan una mayor predisposición a enfermedades autoinmunes, mientras que en los hombres aumenta el riesgo de determinados cánceres de la sangre. Un nuevo estudio analiz...
Read more
The research, co-led by Parc Taulí, studies how infection with the SARS-CoV-2 virus and changes in the hospital environment caused by the pandemic influenced the resistance and virulence of the bacte...
Read more
The study focuses on myelodysplastic syndromes, a group of hematologic diseases characterized by abnormal production of blood cells and with a risk of progression to acute leukemia.
Read more
Un estudio experimental del CBM-CSIC-UAM identifica pequeñas moléculas de ARN que bloquean el crecimiento de células tumorales y abre nuevas vías terapéuticas
Read more
In first line, iadademstat with azacitidine and venetoclax continues to show favorable safety and 100% ORR, with a composite complete remission rate (CRc) of 93% (with 79% CR), and an estimated 12-mon...
Read more
Partnership during the last 8 years leverages VIVEbiotech’s decade of experience manufacturing GMP ex- and in- vivo lentiviral vectors for the advanced therapies sector
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Telum Therapeutics, a biotechnology company leveraging proprietary met...
